Studies indicate that the median overall survival (OS) for patients with ATRX mutations in the context of IDH-mutant gliomas can extend beyond 24–36 months, significantly longer than the 12–15 months commonly observed in primary (IDH wild-type) glioblastomas [2]. This evidence concerns the gene IDH2 and central nervous system cancer.